Table 4.
Comparison of overall survival, disease-free survival, loco-regional relapse, and distant failure along with the total EQD2 doses of various international trials with the present study
| Trial name | Treatment arms | Overall survival (%) | Disease-free survival (%) | Loco-regional relapse (%) | Distant failure (%) | EQD2 |
|---|---|---|---|---|---|---|
| Present study | EBRT (50 Gy) + VBT (6.5 Gy x 2 fractions) | 92.0 | 96.0 | 0.0 | 1.0 | 67.9 Gy |
| VBT (6.5 Gy x 4 fractions) | 84.0 | 88.0 | 2.0 | 3.0 | 35.8 Gy | |
| Sorbe et al. [14] | EBRT (46 Gy median dose) + VBT | 89.0 | 86.7 | 1.5 | 4.6 | Total dose of brachytherapy given ≈ 19.5-23.5 Gy and EBRT ≈ 6-50 Gy |
| VBT alone (3 to 20 Gy in 6-1 fractions) | 90.0 | 86.2 | 5.0 | 6.5 | ||
| PORTEC-2 trial [4] | EBRT (46 Gy in 23 fractions) | 79.6 | 78.0 | 2.1 | 5.7 | 46 Gy |
| VBT only (21 Gy in 3 fractions with HDR or 30 Gy with LDR) | 84.8 | 82.0 | 5.1 | 8.3 | 29.8 Gy | |
| Alektiar et al. [15] | VBT (median HDR-IVRT dose ranged from 6-21 Gy) | 93.0 | 97.0 | – | – | 6-29.8 Gy |
| Laliscia et al. [16] | VBT (21 Gy in 3 fractions) ± adjuvant chemotherapy | 93.0 | 88.0 | 7.9 | 1.6 | 29.8 Gy |
| Draghini et al. [17] | VBT (3-7 fractions x 5-8 Gy ≈ in VBT and 46-50 Gy in EBRT | 77.0 | 63.0 | 18.0 | – | 20-44 Gy for patients receiving only VBT |
EBRT – external beam radiation therapy, VBT – vaginal brachytherapy, EQD2 – equivalent dose at 2 Gy